How can MM patients become involved in the clinical trial networks?
Ibrutinib updates from ASH 2016
Escalating doses and improving outcomes in cutaneous T-cell lymphomas
The importance of diagnosing DLBCL on a molecular level and how it will improve treatment
Importance of prognostic factors in the treatment of CLL and how to assess them